Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

'Gene therapy for retinitis pigmentosa'

Biography

Robert MacLarenRobert MacLaren is Professor of Ophthalmology at the University of Oxford, Consultant Ophthalmologist at the Oxford Eye Hospital, Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology, Honorary Consultant Vitreoretinal Surgeon at Moorfields

Eye Hospital, Faculty Member and Founding Theme Leader of the Moorfields-UCL Institute of Ophthalmology Biomedical Research Centre and an NIHR Senior Investigator. He is also a Fellow of the Royal College of Ophthalmologists, Fellow and former King James IV Professor of Surgery at the Royal College of Surgeons of Edinburgh, Fellow of the American College of Surgeons, Fellow of the Academy of Medical Sciences, Bodley Fellow of Merton College Oxford and Civilian Consultant Advisor to the Royal Navy. He has been a recipient of the ARVO Camras Award for Translational Research, the RP Fighting Blindness Scientist of the Year Award, the American Academy of Ophthalmology Achievement Award and a Euretina Innovation Award. Together with the University of Oxford in 2014 he co-founded Nightstar, a biotechnology company originally based at the Wellcome Trust in London and now listed on NASDAQ, in order to develop further gene therapy treatments for patients with retinal diseases. 

 

Chair: Professor Chris Conlon

All members of the University and NHS clinical staff are welcome.